Answers are grounded in this paper and cite their sources.
The optimal duration and net clinical benefit of dual antiplatelet therapy (DAPT) following transcatheter aortic valve replacement (TAVR) procedure have not been well elucidated in real-world situations. Using nationwide claims data from 2013 to 2021, we selected patients who underwent TAVR were selected and categorized them into two groups: the Short-term DAPT group and the Long-term DAPT group, based on the duration of DAPT (less than or more than 3 months). Propensity-score matching was utilized to balance baseline characteristics. The primary endpoint was the occurrence of net adverse clinical events (NACE) including all-cause death, myocardial infarction, stroke, any coronary and peripheral revascularization, systemic thromboembolism, and bleeding events at 1 year. Survival analyses were conducted using Kaplan-Meier estimation and Cox proportional hazard regression. A total of 2,048 patients meeting the inclusion criteria were selected, and propensity-score matching yielded 685 pairs of patients, categorized into Short-term DAPT and Long-term DAPT groups. In the matched cohort, the mean age was 79.9 ± 5.9 years. Over the 1-year period, NACE occurred in 9.2% of the Short-term DAPT group and 9.9% of the Long-term DAPT group, respectively, without statistical significance (p = 0.645). Short-term DAPT (less than 3 months) and Long-term DAPT (3 months or more) had a similar 1-year NACE rate in patients who successfully underwent transfemoral TAVR.
No takes yet. Share an insight, caveat, or question.
Oh et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: